Development and evaluation of a blood test to assess abdominal symptoms in children with autism

Development OF A Elisa Kit With Ccl 11 Biomarker For Assessing Severity Of Abdominal Symptoms In Autism Spectrum Disorder In Children. - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/101094

Enrollment

Registered

2026-01-14

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G988- Other disorders of nervous system

Interventions

Intervention1: CCL11 levels: estimate CCL11 blood levels in children with autism spectrum disorder sufering from gastro intestinal symptoms Control Intervention1: nil: nil

Eligibility

Inclusion criteria

Inclusion criteria: Children aged 2 12 years, Diagnosed with Autism Spectrum Disorder as per DSM-5 criteria, Presence of gastrointestinal symptoms, Written informed consent from parents/guardians

Exclusion criteria

Exclusion criteria: Children with comorbid neurological disorders like epilepsy and cerebral palsy, Children with allergic disorders, asthma, or on antihistamines Acute infections, chronic inflammatory or autoimmune diseases Long-term immunomodulatory or anti-inflammatory therapy Inadequate or hemolyzed blood samples

Design outcomes

Primary

Measure	Time frame
Serum CCL11 concentration measured by ELISA and its association with gastrointestinal symptom severity scores in children with ASDTimepoint: At enrollment/sample collection	—

Secondary

Measure	Time frame
Comparison of serum CCL11 levels between ASD children with GI symptoms and typically developing childrenTimepoint: During study period	—

Countries

India

Contacts

Public ContactDr Navin

Saveetha medical college hospital

navinu.smc@saveetha.com9487002379

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026